Sangamo BioSciences is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing Zinc finger nucleases which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene. Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS. SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect. The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV. Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.

Nanjing Qizhen Genetic Engineering Co., Ltd., established on 2018-05-10, Business scope includes gene technology,Biotechnology,medical technology,Technological Development of Agricultural Technology,technical consulting,technology transfer,Technical Services;Biological Products Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. It operates through the following segments: Gene Editing Services, Pre-Clinical Pharmacology and Efficacy Evaluation, Animal Models Selling, Antibody Development, and Innovative Drugs Development. The Gene Editing Services segment provides gene editing services. The Pre-Clinical Pharmacology and Efficacy Evaluation segment involves in the provision of pre-clinical pharmacology service for drug efficacy and toxicity evaluation. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment includes one-stop solution from antibody preparation to IND filing for the customer. The Innovative Drugs Development consists of research and developing drugs with a focus on oncology and autoimmune disease therapeutics. The company was founded by Yue Lei Shen on November 13, 2009 and is headquartered in Beijing, China.

Suzhou Lancia Biotechnology Co., Ltd., established on 2016-07-07, Business scope includes biotechnology,Technology development in the biomedical field,technical consulting,Technical Services,technology transfer.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

MGEN Solutions Co., Ltd. engages in the manufacture and sale of appliances and medical equipment. It operates through the following business divisions: Information and Communication Technology, Bio Medical Equipment, and Food. The company was founded on September 21, 1973 and is headquartered in Seoul, South Korea.

Hefei Ruiling Biotechnology Co., Ltd., established on 2017-10-26, Business scope includes biotechnology and product development,technology transfer,Technical Consulting and Technical Services;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies restricted or prohibited by national laws and regulations).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Jiangsu Aierkang Biomedical Technology Co., Ltd., established on 2015-10-30, Business scope includes research and development of biochemical products,Production,Sales;Immunology and Molecular Diagnostic Technology,cell therapy technology,biomedicine,Research and Development of Biomaterials,technology transfer,technical consulting;Pharmaceutical Intermediates,Production of test reagents,Sales;one,Production and sales of Class II medical devices;Self-operated and agent import and export of various commodities and technologies(Except for commodities and technologies that the state restricts the company to operate or prohibits the import and export of).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Beijing Weitongda Biotechnology Co., Ltd., established on 2000-06-27, Business scope includes general cargo;breeding laboratory animals;Provide technical consultation for self-produced products,Technical Services,technology transfer;Sell ​​self-produced products;Import and export,Technology Import and Export,Agent import and export;Office space for rent,commercial space;(Commodities that do not involve state trade management;For commodities subject to quota license management, the application procedures shall be handled in accordance with relevant state regulations).((The enterprise was2003year09moon04Currently a domestic enterprise,At2003year09moon04The day changed to a Sino-foreign joint venture market subject to independently choose operating projects in accordance with the law,Carry out business activities,General cargo and items subject to legal approval,Carry out business activities in accordance with the approved content after approval by relevant departments.))

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Beijing IDMO Co. Ltd. is a company headquartered in Beijing, China, that engages in research and drug development for relevant animal models. It was founded in 2014 by Si Ying Peng, she has been the CEO since that date.

Manufactures pharmaceuticals

Institute For Research In Biomedicine is a Swiss private company located in Bellinzona that provides biomedicine research and development services.\nThe company says this about itself: Founded in 2000 in Bellinzona, the IRB is affiliated with the Università della Svizzera italiana, since 2010. IRB hosts 13 research groups studying defense mechanisms to fight infections, tumors and degenerative diseases. With more than 630 publications in main scientific journals, the IRB has gained international recognition as a center of excellence for immunology and cell biology. Molinari’s laboratory investigates the protein quality control processes determining whether a polypeptide should be secreted, retained in the ER, or selected for degradation. Particular emphasis is given to the study of select rare diseases such as a1-antitrypsin deficiency, LSDs and Charcot-Marie-Tooth 1B neuropathy.